Study meets objective of demonstrating safety and pharmacodynamic response
Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events
Opens way for further deve ...
Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial
• 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supports anti-fibr ...
Data Supports Temelimab's Potential to Treat Disease Progression in MS
Long-term neuroprotective effects confirmed in patients treated up to two years
Sustained benebits on cortical and thalamic atrophy and my ...
Top line results expected in spring 2019
GKT 831 exhibited a favorable safety profile throughout the study
No drop outs or treatment interruptions due to pruritus
2 SAEs recorded in the study, both unrelat ...
10-for-1 reverse stock split: 10 existing shares with par value of €0.10 for 1 new share with par value of €1.00
Start date of the reverse stock split operation: February 27, 2019
Reverse stock split will bec ...
Professor Gareth Thomas of Southampton University Awarded Second Grant from Cancer Research UK for Further Evaluation of GKT831 in Oncology
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharma ...